Bibliografías temáticas / Cell-based immunotherapy / Libros
Siga este enlace para ver otros tipos de publicaciones sobre el tema: Cell-based immunotherapy.

Libros sobre el tema "Cell-based immunotherapy"

Autor: Grafiati
Publicado: 7 de diciembre de 2024

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros

Elija tipo de fuente:

Consulte los 15 mejores mejores libros para su investigación sobre el tema "Cell-based immunotherapy".

Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.

También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.

Explore libros sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.

1

García-Olmo, Damián. Cell therapy. Editado por García-Verdugo José Manuel. New York: McGraw-Hill Interamerica, 2008.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Kang, Chʻang-yul. Pairŏsŭ pektʻŏ ro hyŏngjil toiptoen hangwŏn chesi sepʻo ŭi myŏnyŏk chʻiryoje yuhyosŏng pʻyŏngka mit sihŏmpŏp yŏnʼgu =: Development and estimation of immunotherapeutic cell-based vaccine approaches using antigen presenting cells transduced with viral vector. [Seoul]: Sikpʻum Ŭiyakpʻum Anjŏnchʻŏng, 2007.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Cell-Based Cancer Immunotherapy. Elsevier Science & Technology Books, 2024.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

Borrego, Francisco, Susana Larrucea, Rafael Solana y Raquel Tarazona, eds. NK Cell-Based Cancer Immunotherapy. Frontiers Media SA, 2016. http://dx.doi.org/10.3389/978-2-88919-934-1.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

Santich, Brian H., Nai-Kong Cheung y Christian Klein, eds. Bispecific Antibodies for T-Cell Based Immunotherapy. Frontiers Media SA, 2021. http://dx.doi.org/10.3389/978-2-88966-415-3.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

Dal Col, Jessica, Alejandro López-Soto y Riccardo Dolcetti, eds. Dendritic Cell-Based Immunotherapy in Solid and Haematologic Tumors. Frontiers Media SA, 2020. http://dx.doi.org/10.3389/978-2-88963-726-3.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Ascierto, Paolo A., David F. Stroncek y Ena Wang. Developments in T Cell Based Cancer Immunotherapies. Humana, 2019.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Ascierto, Paolo A., David F. Stroncek y Ena Wang. Developments in T Cell Based Cancer Immunotherapies. Humana, 2015.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
9

Ascierto, Paolo A., David F. Stroncek y Ena Wang. Developments in T Cell Based Cancer Immunotherapies. Humana Press, 2015.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
10

Barisa, Marta. ?dT Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation. Elsevier Science & Technology Books, 2024.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
11

Barisa, Marta. ?dT Cell Cancer Immunotherapy: Evidence-Based Perspectives for Clinical Translation. Elsevier Science & Technology, 2024.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
12

Cifaldi, Loredana, Daniel Olive y James Di Santo, eds. Molecular Strategies Aimed to Boost NK Cell-based Immunotherapy of Cancer. Frontiers Media SA, 2020. http://dx.doi.org/10.3389/978-2-88963-876-5.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
13

Farghaly, Samir A. Adoptive Cell Immunotherapy for Epithelial Ovarian Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0005.

Texto completo
Resumen
The standard management for epithelial ovarian cancer (EOC) is a combination of aggressive debulking surgery with residual tumor of less than 1 cm and platinum-based chemotherapy. However, a high percentage of patients experience disease recurrence. Extensive efforts to find new therapeutic options have been made, albeit cancer cells develop drug resistance and malignant progression occurs. Novel therapeutic strategies are needed to enhance progression-free survival and overall survival of patients with advanced EOC. Several preclinical and clinical studies investigated feasibility and efficacy of adoptive cell therapy (ACT) in EOC. The aim of this chapter is to present an overview of ACT in EOC, focusing on Human Leukocyte Antigen (HLA)-restricted tumor infiltrating lymphocytes and MHC-independent immune effectors such as natural killer and cytokine-induced killer. The available data suggest that ACT may provide the best outcome in patients with low tumor burden, minimal residual disease, or maintenance therapy. Further preclinical studies and clinical trials are needed.
Los estilos APA, Harvard, Vancouver, ISO, etc.
14

Alharbi, Yousef, Manish S. Patankar y Rebecca J. Whelan. Antibody-Based Therapy for Ovarian Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0006.

Texto completo
Resumen
With their role in connecting disease-associated antigens to the cellular immune response, antibodies hold considerable promise as therapeutic agents. This chapter discusses three classes of therapeutic antibodies that have been developed for use in ovarian cancer therapy. The first includes antibodies selected against tumor-associated antigens such as MUC16/CA125, mesothelin, epithelial cell adhesion molecule, and folate receptor α‎. Antibodies in the second class target proteins such as CTLA-4 and PD1 that act as immune response checkpoint receptors. The third class of antibodies target secreted factors that promote tumor growth: targets in this class include vascular endothelial growth factor, cytokines, and chemokines. The development of each of these is described. The chapter also discusses the complications presented by soluble antigens, which serve to limit the applicability of antigens (such as MUC16/CA125) that are both cell-surface associated and circulating and the prospects for the combination of antibody-based immunotherapy and chemotherapy.
Los estilos APA, Harvard, Vancouver, ISO, etc.
15

Abe, Hiroyuki, Amane Sasada, Shigeki Tabata y Minako Abe. Heat Shock Protein Vaccine Therapy for Ovarian Cancer. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780190248208.003.0009.

Texto completo
Resumen
Despite advances in chemotherapeutic regimens, ovarian cancer has a poor prognosis. Therefore important effective treatments are urgently needed. Many studies have reported that the immune system plays a critical role in disease progression and overall survival. One known effective immunotherapy is the dendritic cell (DC)-based vaccine pulsed with tumor-associated antigens. This chapter reports on a method of production of a novel DC-based vaccine. The key technologies are (a) monocyte collection without leukapheresis, (b) monocyte expansion, (c) production of dendritic cells, (d) multiple overlapping long peptides with heat shock protein 70, and (e) combination immunotherapy approach. The next generation of immunotherapy for ovarian cancer will be focused on combination approaches that simultaneously augment immunity while preventing local immune suppression. Possible combinations which might be useful to help patients with ovarian cancer are summarized in this chapter.
Los estilos APA, Harvard, Vancouver, ISO, etc.
También puede estar interesado en las bibliografías sobre el tema "Cell-based immunotherapy" para otros tipos de fuentes:
Artículos de revistas Tesis
Ofrecemos descuentos en todos los planes premium para autores cuyas obras están incluidas en selecciones literarias temáticas. ¡Contáctenos para obtener un código promocional único!

Pasar a la bibliografía